Will US FDA Change Its Conflict Of Interest Policies In Wake Of McKinsey’s Work With Purdue?
Executive Summary
House Oversight Committee members grill McKinsey global managing partner about whether the firm told FDA about its simultaneous work for opioid maker Purdue. Agency says it does not anticipate future contracts with McKinsey until investigations are completed.
You may also be interested in...
US FDA Says Opioid Database Firm With Purdue Pharma Connections Reported No Conflicts
Amid criticism of its contract to evaluate opioid data from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) survey programs, the FDA says federal databases lack the necessary information on opioid misuse.
Opioid Abuse Groups Criticize US FDA For Using Purdue Pharma-Connected Data Firm
The advocates say the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) and its Substance Abuse Treatment Center Programs Combined Survey has conflicts of interest, as well as a connection to the infamous maker of OxyContin.
Drugs From Sponsors ‘Located in Russia,’ Would Be Barred From US FDA Review By House Funding Bill
Language of the amendment cleared by appropriators in response to the Russian war against Ukraine in FDA’s fiscal year funding bill is vague, making impact of the funding ban on industry unclear. Democrats supported the amendment but said they wanted to continue to work on language to avoid “unintended consequences.” FDA would get a 10% bump in non-user fee funds under the bill.